Gilead 2nd CAR-T Therapy Submits Listing Application for Treatment Set Cell Lymphoma

Set cell lymphoma is a rare non-Hodgkin's lymphoma characterized by highly invasive and poor prognosis, mainly in the elderly male population over 60 years of ageClinical manifestations of lymph node swelling, liver and spleen swelling and bone marrow fatigue, more than 80% of patients diagnosed at the advanced stage of the disease, the urgent need for new innovative therapiesKTE-X19 is a CAR-T cell therapy targeted at CD19 and has been awarded the FDA's breakthrough therapy titleIn this Phase II clinical study, codenamed ZUMA-2, patients involved in the trial have received a variety of pre-treatment sprees, including chemotherapy, anti-CD20 monoantigen, BTK inhibitor ibrutinib or acalabrutinib, but the disease has relapsed or developed resistancephase II ZUMA-2 clinical studies showed that PATIENTS TREATED WITH KTE-X19 HAD A ERR of 93%, with 67% OF CRAt the median follow-up time of 12.3 months, 57% of patients' remission was maintainedOf the 28 patients initially treated, 43% survived and were in constant remission without other treatment, with a median follow-up time of 24 monthsThe 12-month progress-free survival rate and total survival rate are expected to be 61 per cent and 83 per cent, respectivelyMedian DoR, PFS, and OS have not yet been reachedsafety, the probability of stage 3 or higher cytokine release syndrome (CRS) and neurological events was 15% and 31%, respectively, without level 5 CRS or neurological events.